AMSTERDAM, Sept 28: A new generation of drugs designed to trigger the immune system to fight cancer is offering the prospect of a ‘clinical cure’ for some melanoma skin cancer patients who until a few years ago were more likely to be facing a swift death. Cancer specialists gathering for a European conference at the weekend said the so-called immunotherapy drugs, a class led by Bristol-Myers Squibb’s Yervoy, or ipilimumab, have transformed an area of oncology in which until recently doctors barely had time to get to know their patients. (agencies)
&&&&
Trending Now
E-Paper
Follow our WhatsApp channel